Atara：FDA A 型會議確認重新提交 tab-cel BLA 的途徑

Atara 與合作夥伴 Pierre Fabre 獲得 FDA 指引，確認現有 Phase 3 ALLELE 試驗數據可支持重新提交 tabelecleucel BLA。重新提交將包含更新數據集，納入更多患者及更長追蹤期。Atara 仍符合 FDA 核准後獲得 3100 萬美元里程碑付款及淨銷售額雙位數權利金的資格。

關鍵事實

申報時間: 2026年8月12日下午08:10
事件: 其他
方向: 中性
公司: ATRAAtara Biotherapeutics, Inc
資產: tabelecleucel
來源: SEC 8-K
可信度: 有出處
里程碑付款: FDA 批准後 $31 million

來源摘錄

EX-99.1 2 atra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress Productive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87% THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a producti

SEC 8-K